Justin M. Watts, MD
Based on advances in the understanding of the disease biology of acute myeloid leukemia (AML), numerous drugs have entered the treatment paradigm, resulting in better outcomes for particularly hard-to-treat patients, said Justin M. Watts, MD.
during the 2019 State of the Science Summit™ on Hematologic Malignancies, Watts, an assistant professor of medicine at the Sylvester Comprehensive Cancer Center, University of Miami Health System, shed light on these promising agents and their impact in the space, discussed remaining challenges, and expressed his hope for an era where most patients with AML will be cured.
OncLive®: What are the recently approved agents in AML and where they fit in the treatment paradigm?
: In younger patients with AML, who traditionally do better than those who are older, we are using these new agents—mostly in combination with induction chemotherapy, or, in some cases, as single agents in relapsed disease. There is gilteritinib if a patient has a FLT3
mutation, or the IDH1/2 inhibitors if they have an IDH1/2
... to read the full story